BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
22 mars 2022 08h30 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
01 mars 2022 08h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
14 févr. 2022 07h30 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference
10 janv. 2022 08h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
15 déc. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
10 nov. 2021 16h30 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
08 nov. 2021 16h30 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
12 oct. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
07 oct. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
06 oct. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular...